uroportal

uroportal.es

El Portal de Urología en Español para profesionales

Búsqueda personalizada
 

 

Documento sin título

Presentación


Los Blogs de UroPortal:
Novedades en UroPortal
Vídeos Urología
Presentaciones Urología
UroInternet
UroGuías
UroPacientes

 

 

Este mes en... Nature Reviews Urology

Sumarios de Revistas

Este mes en... Nature Reviews Urology:

  • Prostate cancer: Twist and Skp2 castration resistance
    A study published in Oncogene has demonstrated the role of S-phase protein kinase 2 (Skp2) in the progression of castration-resistant prostate cancer (CRPC) via Twist-mediated functions including increased epithelial–mesenchymal transition (EMT) and acquisition of cancer stem cells (CSCs).The Twist transcription factor is overexpressed
  • Prostate cancer: Antagonizing AR: MYC affects transcription
    New data, published in EBioMedicine, suggest that c-MYC (MYC) and the androgen receptor (AR) act antagonistically in prostate cancer and that MYC overexpression deregulates the AR transcriptional programme. Understanding this relationship is important for contextualizing biomarkers and therapeutic targets and selecting the optimal course
  • Prostate cancer: Transdifferentiation results in resistance
    New data have shown that transdifferentiation is a mechanism of treatment resistance in castration-resistant prostate cancer (CRPC). These observations could be helpful in stratifying patients who are likely to fail antiandrogen therapy.Zou and colleagues generated a mouse model of Pten and Tp53
  • Prostate cancer: Targeting the core of resistance
    The sequence preference of the glucocorticoid receptor (GR) ligand binding domain (LBD) is similar to that of the androgen receptor (AR) and signalling through the GR results in gene expression that overlaps with that induced by AR signalling. Hence, the GR can be co-opted to
  • Kidney cancer: Tracking and therapy selection using ctDNA
    Despite the approval of various targeted therapies for metastatic renal cell carcinoma (RCC) over the past decade, biomarkers for allocating treatment to specific patients are lacking. The Cancer Genome Atlas (TCGA) project has enabled a deeper understanding of the genomic profile of RCC, but these
  • Prostate cancer: PCA3 as a Grade Reclassification Predictor
    Prostate cancer antigen 3 (PCA3), a noncoding RNA overexpressed in prostate tumours, can provide prognostic information regarding potential for grade reclassification in men enrolled on active surveillance (AS) programmes, according to a recent paper in Prostate Cancer and Prostatic Diseases.Investigators from John Hopkins
  • Prostate cancer: Circulating free DNA as biomarker
    Genomic analysis of serial, circulating free DNA (cfDNA) samples in patients undergoing PARP inhibitor (PARPi) therapy can be used to predict treatment responses and monitor emergence of PARPi resistance mutations, according to a new study in Cancer Discovery.The TOPARP-A trial had found that
  • Surgery: Retzius-sparing RARP improves continence recovery
    Most men undergoing robot-assisted radical prostatectomy (RARP) using the anterior approach eventually obtain urinary continence at 1 year after catheter removal; however, only around 50% are continent at 1 week. Now, data from a randomized-controlled trial indicate superior short-term continence-recovery outcomes following use of a
  • Prostate cancer: New AR co-regulator with dichotomous functions
    A new study shows that Grainyhead-like protein 2 (GRHL2) is a co-regulator of the androgen receptor (AR) in prostate cancer and has dichotomous functions, acting both as an oncogene by enhancing AR signalling and as a suppressor of metastasis-related phenotypes.“Alterations to the expression and
  • Prostate cancer: AZGP1 expression predicts favourable outcomes
    Data from a phase III trial demonstrate that zinc-α 2-glycoprotein (AZGP1) status at radical prostatectomy is predictive of outcomes of patients with prostate cancer, after a median follow-up duration of 15.8 years. Biopsy samples from a total of 347 patients undergoing radical prostatectomy were analysed
  • Kidney cancer: Bap1 and Pbrm1 determine tumour grade
    Many clear cell renal cell carcinomas (ccRCC) harbour ubiquitin carboxyl-terminal hydrolase BAP1 (BAP1) and protein polybromo-1 (PBRM1) mutations. Now, data from genetically modified mouse models indicate that conditional Bap1 or Pbrm1 knockout with Von Hippel–Lindau codeletion results in ccRCC
  • Infection: Intravesical gentamicin ameliorates recurrent UTI
    Data from a retrospective cohort study indicate that regular intravesical instillations of gentamicin reduce the frequency of recurrent UTI. A total of 27 patients with ≥6 culture-confirmed treatment-refractory UTIs in the past year received nightly intravesical gentamicin infusions. Systemic absorption of gentamicin was generally limited,
  • Pain: Chondroitin sulfate is superior to hyaluronic acid
    Data from a comparison study involving patients with interstitial cystitis/bladder pain syndrome indicate the superiority of chondroitin sulfate compared with hyaluronic acid as glucosaminoglycan replacement therapy. Intravesical chondroitin sulfate was superior in terms of 24-hour urinary frequency, nocturia, and interstitial cystitis problem index scores. No
  • Incontinence: The dilemma with comparing efficacy of OAB treatments
    The comparative efficacy of drugs for the management of overactive bladder syndrome (OAB) remains undefined. A new indirect treatment comparison demonstrates similar efficacy of mirabegron versus several antimuscarinic drugs and onabotulinum toxin A in a number of outcome measures. Head-to-head trials of these agents are still required to optimize the management of patients with OAB.
  • Sepsis: Prophylactic antibiotic for prostate biopsy: the carbapenem gamble
    Sepsis is an infrequent but serious adverse risk of transrectal ultrasonography-guided prostate biopsy. A new study evaluated whether the use of single-dose ertapenem, a broad-spectrum antibiotic, resulted in increased carbapenem resistance following biopsy. However, physicians need to carefully consider the risks of antibiotic resistance when balancing the benefit of broad-spectrum antibiosis against a 1% risk of sepsis.
  • Prostate cancer: Comparing quality of life outcomes after prostate cancer treatment
    Life expectancy after primary treatment for localized prostate cancer is long, so the importance of functional outcomes and quality-of-life measures cannot be underestimated. Careful assessment of the data, with an emphasis on patient selection, definition of clinical significance, and length of follow-up duration, is essential.
  • Prostate cancer: ‘The prostate’ in patients with metastatic prostate cancer: to treat or not to treat?
    Advances in understanding of prostate cancer biology and improved treatment options have changed management of metastatic prostate cancer. Escape of the malignancy from the prostatic capsule no longer means that treatment is focused on limiting systemic spread, and data suggest that local treatment of the prostate is beneficial, even in men whose tumour has spread.
  • The potential of organoids in urological cancer research
    Technical advances in the development of organoid systems enable cell lines, primary adult cells, or stem or progenitor cells to develop into diverse, multicellular entities, which can self-renew, self-organize, and differentiate. These 3D organoid cultures have proven to be of value in increasing our understanding
  • The evolution of brachytherapy for prostate cancer
    Brachytherapy (BT), using low-dose-rate (LDR) permanent seed implantation or high-dose-rate (HDR) temporary source implantation, is an acceptable treatment option for select patients with prostate cancer of any risk group. The benefits of HDR-BT over LDR-BT include the ability to use the same source for other
  • Incontinence in the elderly, 'normal' ageing, or unaddressed pathology?
    The prevalence of urinary incontinence and other lower urinary tract symptoms (LUTS) increases in association with increasing age. This effect is more noticeable in men after the seventh decade of life and, in women, postmenopausally. However, the changes in the lower urinary tract, peripheral nervous
 

 

derecho
 
 
Documento sin título

Aviso para pacientes:
Esta página contiene información urológica dirigida a profesionales de la sanidad.
Si tiene algún problema relacionado con esta patología,
consulte con su urólogo o médico de familia.
Si desea información diseñada para pacientes y público general. puede visitar:

Portal de Información Urológica para Pacientes

 

 

Carlos Tello Royloa

 

Actualizada el: 08-Abr-2013

 

uroportal@gmail.com